Mission Statement

Clinuvel’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. Clinuvel develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.

back to top

Read the Latest Blog Posts

Hang in there! Take back control!...

We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...

Too rare to diagnose: Hydroa Vacc...

We recently invited Richard Roosenboom to share his experiences as a parent of a child with a rare disease.... Read more...

Top five sun and skin myths (part...

Myth 4: I need lots of sun exposure to create vitamin D Vitamin D is a contentious topic in modern... Read more...

Watch the Latest Videos

Part Four - The impact of Erythro...

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain f... Watch now

Quick! I need Sunburn Relief! Rem...

There are many remedies available to help provide relief from the symptoms of sunburn. Treatment of sunburn can include:... Watch now

Understanding Vitiligo - Causes &...

Vitiligo is a common pigmentary disorder in which the pigment producing cells of the skin (melanocytes) are absent or do... Watch now

Clinuvel in Focus

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology an... Read more